TY - JOUR
T1 - Economic evaluation of prevention of cystoid macular edema after cataract surgery in patients without diabetes
T2 - ESCRS PREMED study report 4
AU - Simons, Rob W. P.
AU - Wielders, Laura H. P.
AU - Dirksen, Carmen D.
AU - Veldhuizen, Claudette A.
AU - van den Biggelaar, Frank J. H. M.
AU - Winkens, Bjorn
AU - Schouten, Jan S. A. G.
AU - Nuijts, Rudy M. M. A.
AU - ESCRS PREMED Study Grp
N1 - Funding Information:
Supported by the ESCRS. Bausch & Lomb France SAS supplied Yellox eyedrops free of charge. The funding organizations had no role in the design or conduct of this research.
Funding Information:
Supported by the ESCRS. Bausch & Lomb France SAS supplied Yellox eyedrops free of charge. The funding organizations had no role in the design or conduct of this research.
Publisher Copyright:
© 2021 Published by Wolters Kluwer on behalf of ASCRS and ESCRS.
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: To investigate the cost-effectiveness of prophylactic treatments against cystoid macular edema (CME) after cataract surgery in patients without diabetes.Setting: Seven ophthalmology clinics in the Netherlands and Belgium.Design: Prospective cost-effectiveness analysis using data from a European multicenter randomized clinical trial (ESCRS PREMED). Methods: Patients without diabetes planned for expected uneventful cataract surgery were randomized to topical bromfenac (Yellox, n = 242), topical dexamethasone (n = 242), or a combination treatment (n = 238). All relevant resources from a healthcare perspective were included in the cost analysis within a time horizon of 12 weeks postoperatively. The main effectiveness outcome was quality-adjusted life years (QALYs). The main cost-effectiveness outcome was the incremental cost-effectiveness ratio (ICER) based on the cost per QALY.Results: The study comprised 722 patients without diabetes. Total healthcare costs and QALYs were euro 447 (US $562) and 0.174 in the bromfenac group, euro421 (US $529) and 0.179 in the dexamethasone group, and euro442 (US $565) and 0.182 in the combination group. Bromfenac was most costly and least effective (ie, strongly dominated). The ICER was euro6544 (US $8221) per QALY for the combination group compared with the dexamethasone group. Assuming that the willingness to pay is euro 20000 (US $25 126) per QALY, the cost-effectiveness probability was 3%, 32%, and 65% in the bromfenac, dexamethasone, and combination groups, respectively.Conclusions: In patients without diabetes, combination treatment with topical bromfenac and dexamethasone was effective and cost-effective in preventing CME after cataract surgery compared with treatment with either drug alone.J Cataract Refract Surg 2021; 47:331-339 Copyright (c) 2021 Published by Wolters Kluwer on behalf of ASCRS and ESCRS
AB - Purpose: To investigate the cost-effectiveness of prophylactic treatments against cystoid macular edema (CME) after cataract surgery in patients without diabetes.Setting: Seven ophthalmology clinics in the Netherlands and Belgium.Design: Prospective cost-effectiveness analysis using data from a European multicenter randomized clinical trial (ESCRS PREMED). Methods: Patients without diabetes planned for expected uneventful cataract surgery were randomized to topical bromfenac (Yellox, n = 242), topical dexamethasone (n = 242), or a combination treatment (n = 238). All relevant resources from a healthcare perspective were included in the cost analysis within a time horizon of 12 weeks postoperatively. The main effectiveness outcome was quality-adjusted life years (QALYs). The main cost-effectiveness outcome was the incremental cost-effectiveness ratio (ICER) based on the cost per QALY.Results: The study comprised 722 patients without diabetes. Total healthcare costs and QALYs were euro 447 (US $562) and 0.174 in the bromfenac group, euro421 (US $529) and 0.179 in the dexamethasone group, and euro442 (US $565) and 0.182 in the combination group. Bromfenac was most costly and least effective (ie, strongly dominated). The ICER was euro6544 (US $8221) per QALY for the combination group compared with the dexamethasone group. Assuming that the willingness to pay is euro 20000 (US $25 126) per QALY, the cost-effectiveness probability was 3%, 32%, and 65% in the bromfenac, dexamethasone, and combination groups, respectively.Conclusions: In patients without diabetes, combination treatment with topical bromfenac and dexamethasone was effective and cost-effective in preventing CME after cataract surgery compared with treatment with either drug alone.J Cataract Refract Surg 2021; 47:331-339 Copyright (c) 2021 Published by Wolters Kluwer on behalf of ASCRS and ESCRS
KW - NONSTEROIDAL ANTIINFLAMMATORY DRUGS
U2 - 10.1097/j.jcrs.0000000000000449
DO - 10.1097/j.jcrs.0000000000000449
M3 - Article
C2 - 33009281
SN - 0886-3350
VL - 47
SP - 331
EP - 339
JO - Journal of Cataract and Refractive Surgery
JF - Journal of Cataract and Refractive Surgery
IS - 3
ER -